Intranasal Antibody Shows Promise in Protecting Against Influenza
Leiden, Netherlands – A twice-daily nasal spray containing a broadly neutralizing antibody could offer a new line of defense against influenza, potentially protecting individuals during the winter months. Research conducted by a Dutch research group has demonstrated efficacy in both mouse and macaque models, alongside confirmed safety in a human clinical trial. The findings, published in Science Translational Medicine in March 2026, represent a significant step forward in preventative influenza strategies.
The development builds on earlier work originating from Johnson & Johnson, where researchers identified antibodies with broad neutralizing capabilities against both influenza A and influenza B viruses back in 2012. However, initial attempts to confer protection in mice through intravenous administration of these antibodies proved unsuccessful. This led to a pause in clinical development by the company, but the recent research has revitalized interest in this approach, focusing on intranasal delivery as a more effective method.
The Challenge of Influenza and the Search for Broadly Neutralizing Antibodies
Influenza viruses are notorious for their ability to mutate rapidly, leading to the need for annual vaccine updates. These vaccines aim to match the circulating strains, but their effectiveness can vary. A key goal in influenza research is to develop therapies that offer broader protection, less susceptible to viral drift. Broadly neutralizing antibodies (bnAbs) are antibodies that can recognize and neutralize a wide range of influenza virus strains, offering the potential for more durable and effective protection. Science Translational Medicine is a leading journal in this field, frequently publishing research on innovative approaches to combatting infectious diseases.
The initial hurdle faced by Johnson & Johnson researchers was delivering the bnAbs in a way that provided effective protection. Intravenous administration, while effective in some contexts, did not translate to protection against influenza in mouse models. This prompted the Dutch research group to explore alternative delivery methods, ultimately focusing on intranasal administration – directly into the nasal passages, the primary point of entry for the influenza virus.
Intranasal Delivery: A More Effective Route
The research team’s work demonstrated that intranasal administration of the bnAb elicited a robust immune response in the nasal passages, effectively preventing viral replication in both mice and macaques. Crucially, the clinical trial in humans confirmed the safety of this delivery method. While the study focused on safety and initial immune responses, the results pave the way for larger-scale trials to assess the efficacy of the nasal spray in preventing influenza infection in real-world settings.
The Leiden Bio Science Park (LBSP) plays a crucial role in this type of biomedical innovation. According to a press release from Universiteit Leiden, Janssen Biologics, a subsidiary of Johnson & Johnson, is expanding its facilities at the LBSP with new laboratories and offices. This expansion, involving the acquisition of land from the university, underscores the importance of collaboration between academic institutions and pharmaceutical companies in driving medical advancements.
Johnson & Johnson’s Continued Investment in Leiden
Johnson & Johnson’s commitment to the Leiden Bio Science Park is evident in its ongoing investments. In 2023, the company opened a new facility on university grounds along the Emmy Noetherweg, driven by the growth of J&J Innovative Medicine, Biologics. The latest investment, named Optima, will provide additional laboratory and office space to support the production and innovation efforts. The new 7,000 square meter, three-story building will connect to existing facilities via a walkway, creating a unified complex.
Joek Kruiderink, project director of Area Development at the Real Estate Company of Leiden University, emphasized the importance of collaboration with companies at the LBSP. “For the university, collaboration with companies at the LBSP is essential. Growth opportunities for already established companies receive our specific attention, as this can only strengthen the collaboration,” he stated in the Universiteit Leiden press release. This collaborative environment fosters innovation and accelerates the translation of research findings into practical applications.
Looking Ahead: Clinical Trials and Potential Impact
While the initial results are promising, further research is needed to determine the long-term efficacy and optimal dosage of the intranasal antibody spray. Larger clinical trials are planned to assess its ability to prevent influenza infection in diverse populations. The potential impact of this technology is significant, offering a new preventative measure that could complement existing influenza vaccines, particularly for vulnerable populations.
Johnson & Johnson has also been focusing on expanding its innovative medicine capabilities in the Netherlands, as highlighted in a company newsroom article. The company emphasizes its mission to bring life-saving innovations to patients and sees its expansions in Leiden and Sassenheim as crucial to achieving this goal. These expansions also create opportunities for skilled professionals in the region.
Key Takeaways
- A novel intranasal antibody spray shows promise in protecting against influenza.
- Research demonstrates efficacy in animal models and safety in human clinical trials.
- The development builds on earlier work by Johnson & Johnson identifying broadly neutralizing antibodies.
- The Leiden Bio Science Park is a hub for biomedical innovation, fostering collaboration between academia and industry.
- Larger clinical trials are planned to assess the efficacy of the spray in preventing influenza infection.
The next steps involve securing funding for and conducting larger, multi-center clinical trials to confirm these initial findings and determine the optimal use of this intranasal antibody spray. Researchers will also be investigating the duration of protection and the potential for the spray to be effective against emerging influenza strains. We will continue to follow this story as it develops and provide updates on the progress of clinical trials and regulatory approvals.
What are your thoughts on this potential new approach to influenza prevention? Share your comments below, and please share this article with your network.
Keep reading